Altimmune, a clinical-stage biopharmaceutical company in Gaithersburg, Maryland, develops peptide-based therapeutics for obesity and liver diseases, including the lead candidate pemvidutide. The company has completed Phase II trials for both pemvidutide and HepTcell, targeting metabolic dysfunction and hepatitis B.
ALT has been in the news recently: Altimmune, Inc. experienced a 53.2% decline in its stock price, falling from $7.71 to $3.61, after failing to meet expectations in a clinical trial. Following this drop, multiple law firms, including Gross Law Firm and Robbins LLP, are investigating the company for allegedly misleading investors.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
